Why holding-time in medicated drinking water is limited by pH-driven lactone hydrolysis

Siwei Chuanxinlian Powder Veterinary Grade API is pre-blended with anhydrous dextrose and a citric acid–sodium citrate buffer to hold the reconstituted stock solution within pH 4.5–6.0. In this range the andrographolide-type diterpene lactone remains predominantly in the closed-ring form and hydrolysis to ring-opened degradation products is retarded. Above pH 8.2, a condition common in hard bore-hole water with bicarbonate alkalinity exceeding 250 mg/L as CaCO₃, ring-opening accelerates and the solution becomes turbid as calcium salts of botanical organic acids precipitate. A pin-milled API fraction with D90 < 75 µm is required before dry blending because larger fibrous fragments block the check valves of diaphragm proportioners. In a 1:100 draw-ratio medicator, a stock solution at 20–50 g/L delivers 0.2–0.5 g of dry powder per litre to the drinking line. The stock tank requires continuous recirculation at 30–40 L/min to keep insoluble non-diterpene plant fibres suspended; settling velocities can exceed 0.02 m/min when mixing stops. Production-scale poultry installations have shown nozzle occlusion can begin within 8 h if stock viscosity rises above 10 mPa·s at 20 °C. The medicated water is therefore used within 4–6 h unless a preservative system validated against Ph. Eur. 5.1.3 is included. Free chlorine above 1.0 mg/L in the water supply is considered an incompatibility because oxidative degradation of the unsaturated lactone fraction is difficult to monitor in the barn environment.

Batch records from piglet nursery proportioner lines indicate that in-line dosing accuracy can fall by 3–7% when the stock tank is refilled without cleaning the discharge filter. A 240 µm stainless steel mesh filter retains gelatinous polysaccharide fines that concentrate during continuous medication. A duplex filter arrangement is used so that backflushing can proceed without interrupting the medication cycle. Because the dry API is hygroscopic, open bags exposed to relative humidity above 60% gain sufficient moisture to raise the water activity of the premix above 0.6, and hopper caking then produces variable delivery from the dosing pump. Mixing energy should not exceed 15 kW/t in a ribbon mixer; shear-induced product temperatures above 35 °C accelerate marker loss in the presence of residual moisture.

Direct compression of the API as a sole tablet component is rarely possible on rotary presses operating above 60,000 tablets/h because the plant fibre fraction lowers bulk density to approximately 0.35–0.45 g/mL and produces Carr index values above 28. The powder is hygroscopic, and moisture content at 50% RH can exceed 5.0%, causing sticking to polished tooling. A wet-granulated tablet formulation used in pilot batches contains 30–40 wt% API, 42 wt% microcrystalline cellulose PH 102, 10 wt% lactose monohydrate, 3 wt% crospovidone, 3 wt% povidone K30, and 1 wt% magnesium stearate. Granulation is performed in a high-shear mixer at impeller speed 300 rpm and chopper speed 1500 rpm. Purified water is sprayed at 50–100 g/min until granule moisture reaches 12–15%. The wet mass is passed through a 1.0 mm screen and dried in a fluid-bed dryer at inlet air 55–60 °C to a final loss-on-drying of 2.0–3.5%. After dry milling through a 0.8 mm conical sieve and lubrication, the press is adjusted to produce hardness of 5–8 kp and friability below 1.0% per Ph. Eur. 2.9.7. Disintegration time is specified below 15 min in water at 37 °C. Uniformity of dosage units is assessed according to Ph. Eur. 2.9.40 with an acceptance value not exceeding 15. Alu-alu blister packaging is used when warehouse relative humidity exceeds 60%, since the botanical matrix can discolour from cream to tan within 30 days in PVC/PVDC blister material.

Bacterial endotoxin control in injectable dosage forms derived from botanical powder

Injectable dosage forms based on the API require removal of the non-soluble plant matrix before sterile filtration. The marker diterpene lactone is poorly water-soluble; published aqueous solubility data at 25 °C generally fall below 0.1 mg/mL, although the value varies with crystalline form and particle size. A co-solvent system containing propylene glycol 20–40% v/v and ethanol 5–10% v/v in water for injection is used after an initial maceration step in hot purified water at 70–80 °C for 30 min. The extract is cooled to 25 °C and passed through a 0.45 µm prefilter. Polysaccharide fouling can raise transmembrane pressure above 1.5 bar within 20 min; a depth filter with nominal retention rating of 1.0 µm is therefore installed before the membrane train. Terminal sterilisation at 121 °C for 15 min is not automatically suitable because published degradation kinetics for this specific botanical configuration are limited. Aseptic filtration through a 0.22 µm membrane in an ISO 14644-1:2015 Grade A environment is the conservative route when the co-solvent load exceeds 20% v/v.

Bacterial endotoxin is controlled to below 0.5 EU/mL in the final solution per Ph. Eur. 2.6.14. Raw botanical APIs can carry endotoxin levels above this limit, so depyrogenation of the process stream is required. Ultrafiltration with a 10 kDa molecular weight cut-off retains endotoxin aggregates while allowing the diterpene lactone to pass, but flux rates can fall by 30–40% as polysaccharides deposit on the membrane. A multi-dose vial presentation incorporates 1.5% v/v benzyl alcohol as an antimicrobial preservative. Injection-site tolerance testing in the target species is mandatory because propylene glycol concentrations above 60% v/v are associated with haemolysis in small ruminants. Finished vials are inspected for visible particles per Ph. Eur. 2.9.20. Particulate contamination is often traced to incomplete extraction of plant cell debris rather than packaging, and visible particle counts above 10 per container trigger a review of the depth-filtration batch record.

When feed premix segregation arises from electrostatic botanical fines

The dry API can develop a positive electrostatic charge after hammer milling and may adhere to the stainless-steel walls of a twin-shaft paddle mixer within 5 min of dry mixing. Batch records from a 2,000 kg ribbon mixer show that unattached fines can accumulate on end plates at 0.3–0.5% of batch mass, producing assay variance above 10% relative standard deviation. To control segregation, soybean oil or mineral oil is sprayed at 0.5–1.0% w/w after the first 2 min of dry blending. The API is extended to a 5% w/w intermediate premix on a carrier of wheat bran or rice hulls and then incorporated into complete feed at 0.1–0.5% w/w according to the target daily intake. Mixing proceeds for 6–10 min at 20–30 rpm, with fill level held at 60–70% of gross volume. Pellet conditioning at 75–85 °C for 30–60 s is acceptable only when feed moisture remains below 16%; above this threshold pellet quality softens and marker loss increases. Post-pelleting liquid application in a vacuum coater at 0.8–1.0 bar avoids the thermal cycle but requires the API to be dispersed in a palatable oil phase with D90 < 50 µm. Feed hygiene is maintained under Regulation EC 183/2005 and, for export markets, under GMP+ or ISO 22000 certification. Carryover from bucket elevators and drag conveyors is cleaned between batches to prevent cross-contact above 0.1% of the previous batch mass.

At the capsule-filling stage for companion-animal or small-holder oral dosing, the API is granulated into 0.8–1.2 mm spheres to improve flow and reduce dust. Extrusion-spheronization uses a wet mass of 45 wt% API, 35 wt% microcrystalline cellulose, 18 wt% lactose monohydrate, and 2 wt% croscarmellose sodium. Purified water is added to a wet-mass moisture of 48–52%, and the mass is extruded through a 0.8 mm screen at screw speed 30–40 rpm. Spheronization at 700–900 rpm for 3–5 min produces pellets with aspect ratio below 1.2. The pellets are dried at 50–55 °C to a loss-on-drying below 3.0% and filled into size #1 hard gelatin capsules. Dissolution testing is performed using Ph. Eur. 2.9.3 apparatus II at 75 rpm in 900 mL of 0.1% sodium lauryl sulfate solution. A release specification of not less than 80% in 45 min is used as an internal benchmark for plant-derived APIs, but published monographs for this specific product configuration are limited. The dominant failure mode on high-speed capsule fillers is ejection of low-density fines from the die when the powder bed is too dry; room air is therefore maintained at 35–45% RH.

Fluid-bed granulation endpoints are dictated by the binder glass transition rather than inlet temperature

For oral granules filled into sachets or reconstituted to a suspension, top-spray fluid-bed granulation is performed with a 1.2 mm nozzle and atomising air pressure of 1.5–2.0 bar. Inlet air temperature is set at 65–70 °C, but the critical endpoint is the product bed temperature of 40–45 °C and exhaust relative humidity of 25–35%. If product temperature exceeds 45 °C, the botanical powder darkens from cream to tan and oxidation of conjugated double bonds may reduce marker recovery. The binder solution contains povidone K30 or hydroxypropyl methylcellulose at 2–4% w/w in purified water and is sprayed at 50–100 g/min per kg of dry charge. Granule growth is monitored by laser diffraction per ISO 13320:2020; the target D50 is 150–250 µm and D90 is below 500 µm. Finished granules have bulk density 0.45–0.55 g/mL, tapped density 0.55–0.65 g/mL, and Hausner ratio below 1.25. Moisture content is controlled at 1.8–2.8% before packaging. The dry granules are filled into sachets of 5 g, 10 g, and 25 g; each sachet is reconstituted in 250 mL of potable water before oral drenching. When the difference between product temperature and wet-bulb temperature falls below 10 °C, drying stalls and uncontrolled agglomeration produces clusters above 2.0 mm that fail screen classification.